Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

2018 Drug Approvals

1/23/2019

 
The FDA approved 59 investigational drugs to be released to distribution in 2018, beating the 2017 total of 46. The number of approvals in 2018 also sets a record for the number of new drug approvals in a single year. The previous highest annual total was 53 in 1996. 
​
Almost 3/4 of the drugs (43) had priority reviews. Almost half of the priority reviews were filed as orphan drugs (34), while 58% were for rare diseases, 41% had Fast Track status and almost a quarter were designated as Breakthrough Therapies (14). Through its work in streamlining and optimizing drug reviews, 71% of drugs were first approved in the U.S. All drugs were approved by or before their PDUFA dates. 
 
The FDA was not the only one that increased the number of new drugs approved in 2018. The European Medicine Agency approved 42 new drugs last year, which is up from 35 in 2017.  This included 21 drugs that were designated Orphan Drugs. As in the U.S., the largest therapeutic group were the 23 oncology drugs approved.
 
Congress passed Right-To-Try legislation in the spring of 2018. Formal guidelines have not been announced, but ERC-1671 (Gliovacfrom Epitopoietic Research Corp)became the first right to try drug in the fall.
 
Notable approvals in 2018
 
A total of 14 infectious disease drugs that included:
  • Baloxavir marboxil(Xofluza), was approved as a single dose influenza treatment that reduced flu symptoms similar to 5-days of oseltamivir.
  • Three drugs for MDR bacterial infections
    • Eravacycline (Xerava) was approved for the treatment of complicated intra-abdominal infections.
    • Omadacycline (Nuzyra) was approved for the treatment of community-acquired pneumonia and acute skin and skin structure infections.
    • Plazomicin (Zemdri) was approved for the treatment of complicated urinary tract infections and is the first aminoglycoside approved since amikacin.
  • Five drugs or new combinations for the treatment of HIV
    • Bictegravir, emtricitabine, tenofovir alafenamide (Biktarvy) 
    • Doravirine (Pifeltro) 
    • Doravirine, lamivudine and tenofovir disoproxil fumarate (Delstrigo) 
    • Ibalizumab (Trogarzo) was approved for multi-drug resistant HIV 
    • darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (Symtuza)
A total of seven neurology drugs that included:
  • Three CGRP for migraine prophylaxis 
    • Erenumab (Aimovig) 
    • Fremanezumab (Ajovy)
    • Galcanezumab(Emgality)
  • The first cannabidiol (Epidiolex) was approved for the the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.
A total of six drugs for genetic diseases that included:
  • Two drugs for the treatment of the polyneuropathy of hereditary transthyretin mediated amyloidosis. 
    • Patisiran(Onpattro)
    • Inotersen (Tegsedi)
  • Migalastat (Galafold) for the treatment of Fabry disease caused by a genetic mutation
  • Burosumab (Crysvita) for the treatment of X-linked hypophosphatemia
  • Elapegademase(Revcovi) for the treatment of adenosine deaminase severe combined immune deficiency
  • Lanadelumab (Takhzyro) for the treatment of hereditary angioedema
A total of 16 oncology drugs were approved including:
  • More treatments for hematologic cancers than for solid tumors.
  • Several drugs for the treatment of genetically specified tumors were approved.
    • Binimetinib (Mektovi) + Encorafenib(Braftovi) for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation 
    • Ivosidenib(Tibsovo) for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
    • Dacomitinib(Vizimpro) for the treatment of EGFR-mutated non-small cell lung cancer
    • Lorlatinib (Lorbrena) for the treatment of ALK-positive NSCLC
    • Talazoparib (Talzenna) for the treatment of BRCA-mutated, HER2-negative breast cancer
    • Larotrectinib (Vitrakvi) for the treatment of tumors feature a neurotrophic receptor tyrosine kinase gene fusion
    • Gilteritinib(Xospata) for the treatment of acute myeloid leukemia with an FLT3mutation
Specialty Pharmacy Times listed their top specialty pharmaceuticals approved in 2018
  • Erenumab (Aimovig) for tprophylaxis of migraine headaches 
  • Lanadelumab (Takhzyro) for the treatment of hereditary angioedema
  • Baricitinib (Olumiant) for the treatment of rheumatoid arthritis
  • Cannabidiol (Epidiolex) for the treatment of Lennox-Gastaut syndrome and Dravet syndrome
  • Tildrakizumab(Ilumya) for the treatment of plaque psoriasis
  • Tofacitinib (Xeljanz) for the treatment of active ulcerative colitis
Miscellaneous drug approvals
  • ElagolixOrilissa) for the treatment of pain associated with endometriosis
  • Coagulation factor Xa (Andexxa) for reversal of factor Xa inhibitors
  • Tezacaftor/ivacaftor (Symdeko) for the treatment of cystic fibrosis. This two drug combination will become a three drug combination in the next 1-3 years, when either VX-659 and VX-445 (correctors) are added to the two drug combination.
Resources
Medscape's Review of New Drug Approvals
 
The FDA's 2018 Drug Therapy Approvals
 
The FDA's List of 2018 Drug Approvals by Medical Specialty
 
PM Live's Review of European
2018 Drug Approvals 
 
Specialty Pharmacy Time's Review of Top Ten Specialty Pharmaceutical Approvals

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.